Interesting the slide on manufacturing and toxicity measurements. If they really have everything sorted for manufacturing by end 2016 that's a real achievement. You can argue if Ph III doesn't get up it's money down the drain (see ACL) but to me it's prudent risk management to get this sorted out now.
I'm really looking forward to the AGM this year. If TBI gets up it'll be a corker.
Ann: Neuren Investor Presentation, 11 January 2016, page-6
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.56 |
Change
-0.360(2.59%) |
Mkt cap ! $1.733B | |||
| Open | High | Low | Value | Volume |
| $13.94 | $13.96 | $13.50 | $6.421M | 470.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1643 | $13.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.61 | 3100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |